|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
In older women, those with the CYP 19 GA and GG genotypes had an increased prevalence of osteoporosis (P = 0.04) and fractures (P = 0.003).
|
14715870 |
2004 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
Thus, aromatase is an attractive osteoporosis candidate gene.
|
17391072 |
2007 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In older women, those with the CYP 19 GA and GG genotypes had an increased prevalence of osteoporosis (P = 0.04) and fractures (P = 0.003).
|
14715870 |
2004 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
For women with breast cancer, bone mineral density screening is recommended with long-term aromatase inhibitor use because of the risk of osteoporosis due to estrogen deficiency.
|
29794680 |
2018 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Women diagnosed with breast cancer between 2006 and 2015 and treated with tamoxifen or aromatase inhibitors (n = 36,472) were stratified according to low (without osteoporosis diagnosis nor bisphosphonates exposure) or high (with osteoporosis and/or treated with bisphosphonates) fracture risk.
|
31596961 |
2020 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Osteoporosis treatment, including vitamin D and bisphosphonates, is associated with a 50% reduction of relapse and death in women treated with aromatase inhibitors for ER+ breast cancer.
|
30036740 |
2018 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, CYP17 and CYP19 gene polymorphisms were found to be associated with osteoporosis in postmenopausal women in Turkey.
|
21948762 |
2011 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The osteoporosis incidence in postmenopausal patients on aromatase inhibitors (AI) is much higher than in those on tamoxifen, and adverse effects other than musculoskeletal disorders are less on AI than on tamoxifen.
|
31172521 |
2019 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We detected four genes (DBP, LRP5, CYP17, and RANK) that showed highly suggestive associations (10,000-permutation derived empirical global p < or = 0.01) with spine BMD/OP; four genes (CYP19, RANK, RANKL, and CYP17) highly suggestive for hip BMD/OP; and four genes (CYP19, BMP2, RANK, and TNFR2) highly suggestive for UD BMD/OP.
|
17002564 |
2006 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Looking for markers related to osteoporosis, we have analyzed five single nucleotide polymorphisms located in genes related to the estrogen pathway, Follicle Stimulating Hormone Receptor (FSHR) gene, the CYP19 aromatase (CYP19A1) gene, the Estrogen Receptor alpha (ESR1) gene, the Estrogen Receptor beta (ESR2) gene and the Nuclear Receptor Interacting Protein 1 (NRIP1) gene in 265 unrelated postmenopausal women.
|
16530497 |
2006 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in the CYP19 and AR genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study.
|
14517714 |
2004 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
By reviewing the recent literature, it was found that the genetic variations of CYP19, CYP1A2, CYP3A4, and 17 beta-HSD are important factors affecting the estradiol serum level, and may be closely related to the development of osteoporosis.
|
11360662 |
2000 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer patients in the MA.27 trial had similar outcomes with steroidal aromatase inhibitor (AI) exemestane and nonsteroidal anastrozole.AIs increase the risk of osteoporosis.
|
28464211 |
2017 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The analysis of the CYP19A1 rs700518 polymorphism showed that heterozygotes were more common in the group with osteoporosis (58.3%) than in the control group (52.8%).
|
30855728 |
2019 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
For women with breast cancer, bone mineral density screening is recommended with long-term aromatase inhibitor use because of the risk of osteoporosis due to estrogen deficiency.
|
29794673 |
2018 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The objective of the investigation was to study the relationship of a set of single nucleotide polymorphisms (SNPs) of the aromatase gene with osteoporosis and determine their functional influence on gene transcription.
|
17118999 |
2007 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
|
29520506 |
2019 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
It is well known that anti-estrogen therapy (AET), especially aromatase inhibitors (AI), is associated with rapid bone loss and thus increases the risk of osteoporosis.
|
29981903 |
2018 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Despite their effectiveness in reducing tumor recurrence, aromatase inhibitors have adverse effects on the cardiovascular system and increase osteoporosis and bone fractures.
|
25023195 |
2014 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Thus, aromatase is an attractive osteoporosis candidate gene.
|
17391072 |
2007 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In multivariable analyses, osteoporosis was positively associated with the aromatase inhibitor (AI) sequential treatment after tamoxifen (HR, 3.14; 95% CI, 1.44-6.88; P = .004) but was more pronounced with AI use as upfront monotherapy (HR, 5.53; 95% CI, 1.46-20.88; P = .012).
|
30413856 |
2019 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Furthermore, current therapies using aromatase inhibitors have side effects on bone resulting in development of osteoporosis in some patients.
|
17215075 |
2007 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Dysfunction of the enzyme aromatase (CYP19) is associated with endocrine pathologies such as osteoporosis, impaired fertility and development of hormone-dependent cancers.
|
20723554 |
2010 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Osteoporosis is a major side effect of aromatase inhibitors (AIs), which are greatly effective in the treatment of breast cancer.
|
31393399 |
2019 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Osteoporosis (OP) risk factor assessment and bone mineral density (BMD) testing are frequently omitted at baseline in aromatase inhibitor (AI) studies, which may lead to misinterpretation of AI associated bone loss.
|
30939140 |
2019 |